The themes Treace Medical Concepts is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Built from Treace Medical Concepts, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$5.04+3.4%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 6, 2026
Company outlook: revenue of $206M to $210M for Fiscal year 2026 — down 2.2% on a year earlier ($212.7M)
Just reported
From Treace Medical Concepts's results release of November 6, 2026; its quarterly report has since been filed.
Actual
$48.3M
-3.9% y/y
+6.3% q/q
Guided
—
No guide given
Actual
-$0.19
Guided
—
No guide given
Actual
-$11.5M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade D-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 20 quarters of Treace Medical Concepts, Inc.’s grade history. The other 18 go back to March 2022.